Nanocrystals as a master key to deliver hydrophobic drugs via multiple administration routes

MB McGuckin, J Wang, R Ghanma, N Qin… - Journal of Controlled …, 2022 - Elsevier
The poor aqueous solubility of many approved drugs and most new chemical entities poses
a challenge to drug delivery scientists working in academic and industrial labs. Despite the …

Long-acting parenteral drug delivery systems for the treatment of chronic diseases

AB **dal, AR Bhide, S Salave, D Rana… - Advanced Drug Delivery …, 2023 - Elsevier
The management of chronic conditions often requires patients to take daily medication for an
extended duration. However, the need for daily dosing can lead to nonadherence to the …

Challenges and opportunities in metastatic breast cancer treatments: Nano-drug combinations delivered preferentially to metastatic cells may enhance therapeutic …

J Yu, Q Mu, M Fung, X Xu, L Zhu, RJY Ho - Pharmacology & therapeutics, 2022 - Elsevier
Despite advances in breast cancer treatments and related 5-year survival outcomes,
metastatic breast cancer cures remain elusive. The current standard of care includes a …

Enhanced intradermal delivery of nanosuspensions of antifilariasis drugs using dissolving microneedles: a proof of concept study

AD Permana, MTC McCrudden, RF Donnelly - Pharmaceutics, 2019 - mdpi.com
Conventional oral administration of antifilariasis drugs results in nonspecific targeting of the
drugs and the intradermal delivery of nanoparticles with sizes of< 100 nm could be used to …

[HTML][HTML] Battle of the milky way: Lymphatic targeted drug delivery for pathogen eradication

A Taheri, KE Bremmell, P Joyce… - Journal of Controlled …, 2023 - Elsevier
Many viruses, bacteria, and parasites rely on the lymphatic system for survival, replication,
and dissemination. While conventional anti-infectives can combat infection-causing agents …

An ultralong-acting tenofovir ProTide nanoformulation achieves monthslong HBV suppression

S Das, W Wang, M Ganesan, F Fonseca-Lanza… - Science …, 2022 - science.org
Treatment of chronic hepatitis B virus (HBV) requires lifelong daily therapy. However,
suboptimal adherence to the existing daily therapy has led to the need for ultralong-acting …

Nanocrystals for controlled delivery: state of the art and approved drug products

RS Kalhapure, S Palekar, K Patel… - Expert opinion on drug …, 2022 - Taylor & Francis
Introduction Controlled/extended-release formulations offer numerous benefits over
conventional especially reduced side effects, improved therapeutic outcomes, and high …

Chronic hepatitis B infection: New approaches towards cure

M Ogunnaike, S Das, SS Raut, A Sultana, MU Nayan… - Biomolecules, 2023 - mdpi.com
Chronic hepatitis B virus (HBV) infection leads to the development of cirrhosis and
hepatocellular carcinoma. Lifelong treatment with nucleotides/nucleoside antiviral agents is …

Targeted delivery of lopinavir to HIV reservoirs in the mesenteric lymphatic system by lipophilic ester prodrug approach

C Qin, YJ Chu, W Feng, C Fromont, S He, J Ali… - Journal of Controlled …, 2021 - Elsevier
The combined antiretroviral therapy (cART) can efficiently suppress HIV replication, but the
cessation of cART usually results in viral rebound, mostly due to the presence of viral …

Physiologically based pharmacokinetic model validated to enable predictions of multiple drugs in a long-acting drug-combination nano-particles (DCNP): confirmation …

S Perazzolo, DD Shen, AM Scott, RJY Ho - Journal of Pharmaceutical …, 2024 - Elsevier
Abstract Drug-Combination Nanoparticles (DcNP) are a novel drug delivery system
designed for synchronized delivery of multiple drugs in a single, long-acting, and targeted …